Glycyrrhizic acid (GCA) as 11β-hydroxysteroid dehydrogenase inhibitor exerts protective effect against glucocorticoid-induced osteoporosis

Journal of Bone and Mineral Metabolism

Volumn 31, Issue 3, 2013, Pages 262-273

  Ramli, Elvy Suhana Mohd ^a   Suhaimi, Farihah ^a   Asri, Siti Fadziyah Mohamad ^a   Ahmad, Fairus ^a   Soelaiman, Ima Nirwana ^a  

^a DEPARTMENT OF PHARMACOLOGY   (Malaysia)

Author keywords

11 Hydroxysteroid dehydrogenase type 1; Dexamethasone; Glucocorticoids; Glycyrrhizic acid; Osteoporosis

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTICOSTERONE; DEXAMETHASONE; GLYCYRRHIZIC ACID; OSTEOCALCIN; PYRIDINOLINE;

ADRENALECTOMY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ADRENALECTOMY; AMINO ACIDS; ANIMALS; BIOMECHANICAL PHENOMENA; BONE AND BONES; CORTICOSTERONE; DEXAMETHASONE; DIETARY SUPPLEMENTS; ENZYME INHIBITORS; GLUCOCORTICOIDS; GLYCYRRHIZIC ACID; IMMUNOHISTOCHEMISTRY; MALE; OSTEOCALCIN; OSTEOPOROSIS; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84878570365     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-012-0413-x     Document Type: Article

References (51)

1. Raisz LG (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115:3318-3325
2. Melton LJ III (2003) Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 18:1139-1141
3. Cheng SL, Zhang SF, Avioli LV (1996) Expression of bone matrix proteins during dexamethasone-induced mineralization of human bone marrow stromal cells. J Cell Biochem 61:182-193
4. Iba K, Chiba H, Sawada N, Hirota S, Ishii S, Mori M (1995) Glucocorticoids induce mineralization coupled with bone protein expression without influence on growth of a human osteoblastic cell line. Cell Struct Funct 20:319-330
5. Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319-1328
6. Van der Meulen MC, Jepsen KJ, Mikić B (2001) Understanding bone strength: size isn't everything. Bone 29:101-104
7. Carter DR, Beaupré GS (1990) Effects of fluoride treatment on bone strength. J Bone Miner Res Suppl 1:S177-S184
8. Turner CH (2002) Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 13:97-104
9. Lo Cascio V, Bonucci E, Imbimbo B, Ballanti P, Tartarotti D, Galvanini G, Fuccella L, Adami S (1984) Bone loss after glucocorticoid therapy. Calcif Tissue Int 36:435-438
10. Lo Cascio V, Kanis JA, Beneton MN, Bertoldo F, Adami S, Poggi G, Zanolin ME (1995) Acute effects of deflazacort and prednisone on rates of mineralization and bone formation. Calcif Tissue Int 56:109-912
11. Dalle Carbonare L, Arlot ME, Chavassieux PM et al (2001) Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16:77-103
12. Canalis E (2005) Mechanisms of glucocorticoid action in bone. Curr Osteoporos Rep 3:98-102 (review)
13. Pereira RM, Delany AM, Canalis E (2001) Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 28:484-490
14. Pereira RC, Delany AM, Canalis M (2002) Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone 30:685-691
15. Sciaudone M, Gazzerro E, Priest L, Delany AM, Canalis E (2003) Notch 1 impairs osteoblastic cell differentiation. Endocrinology 144:5631-5639
16. Dempster DW, Arlott MA, Meunier PJ (1983) Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 35:410-417
17. Chavassieux PM, Arlot ME, Roux JP, Portero N, Daifotis A, Yates AJ, Hamdy NA, Malice MP, Freedholm D, Meunier PJ (2000) Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 15:754-762
18. Weinstein R, Jilka R, Parfitt A, Manolagas S (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274-282
19. Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC (2002) Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 109:1041-1048
20. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS (2006) Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147:5592-5599
21. Kim CH, Cheng SL, Kim GS (2006) Effects of dexamethasone on proliferation, activity, and cytokine secretion of normal human bone marrow stromal cells: possible mechanisms of glucocorticoid-induced bone loss. J Endocrinol 162:371-379
22. Delany AM, Durant D, Canalis E (2001) Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol 15:1781-1789
23. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382-4389
24. Rubin J, Biskobing DM, Jadhav L, Fan D, Nanes MS, Perkins S, Fan X (1998) Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells. Endocrinology 139:1006-1012
25. White PC, Mune T, Agarwal AK (1997) 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18:135-156
26. Stewart PM, Krozowski ZS (1999) 11 beta-Hydroxysteroid dehydrogenase. Vitam Horm 57:249-324
27. Stewart PM, Whorwood CB (1994) 11 beta-Hydroxysteroid dehydrogenase activity and corticosteroid hormone action. Steroids 59:90-95
28. Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M, Stewart PM (2000) Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone. Bone 27:375-381
29. Phillipov G, Palermo M, Shackleton CH (1996) Apparent cortisone reductase deficiency: a unique form of hypercortisolism. J Clin Endocrinol Metab 81:3855-3860
30. Cooper MS, Blumsohn A, Goddard PE, Bartlett WA, Shackleton CH, Eastell R, Hewison M, Stewart PM (2003) 11beta-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone. J Clin Endocrinol Metab 88:3874-3877
31. Ploeger B, Mensinga T, Sips A, Seinen W, Meulenbelt J, DeJongh J (2001) The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modeling. Drug Metab 33:125-147
32. Stewart PM, Wallace AM, Atherden SM, Shearing CH, Edwards CR (1990) Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and liquorice on 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Sci (Lond) 78:49-54
33. Lems WF, Van Veen GJ, Gerrits MI, Jacobs JW, Houben HH, Van Rijn HJ, Bijlsma JW (1998) Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers. Br J Rheumatol 37:27-33
34. Prummel MF, Wiersinga WM, Lips P, Sanders GT, Sauerwein HP (1991) The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 72:382-386
35. Eijken M, Hewison M, Cooper MS, de Jong FH, Chiba H, Stewart PM, Uitterlinden AG, Pols HA, van Leeuwen JP (2005) 11beta-Hydroxysteroid dehydrogenase expression and glucocorticoid synthesis are directed by a molecular switch during osteoblast differentiation. Mol Endocrinol 19:621-631
36. Moisan MP, Seckl JR, Edwards CRW (1990) 11β-hydroxysteroid dehydrogenase bioactivity and messanger RNA expression in rat forebrain: localization in hypothalamus, hippocampus and cortex. Endocrinology 127:1450-1455
37. Moisan MP, Seckl JR, Monder C, Agarwal PC, Edwards CRW (1990) 11β-hydroxysteroid dehydrogenase mRNA expression, bioactivity and immunoreactivity in rat cerebellum. Neuroendocrinology 2:853-858
38. Haque T, Mandu-Hrit M, Rauch F, Lauzier D (2006) Immunohistochemical localization of Bone Morphogenetic protein-signaling Smads during Long-bone Distraction Osteogenesis. J Histochem Cytochem 54:407-415
39. Haffa A, Krueger D, Bruner J, Engelke J, Gundberg C, Akhter M, Binkley N (2000) Diet- or warfarin-induced vitamin K insufficiency elevates circulating undercarboxylated osteocalcin without altering skeletal status in growing female rats. J Bone Miner Res 15:872-878
40. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
41. Ima Nirwana S, Suhaniza S (2004) Effects of tocopherols and tocotrienols on Body composition and bone calcium content in adrenalectomized rats replaced with Dexamethasone. J Med Food 7:45-51
42. Elvy Suhana MR, Farihah HS, Faizah O, Nazrun AS, Norazlina M, Norliza M, Ima-Nirwana S (2011) Effect of 11β-HSD1 dehydrogenase activity on bone histomorphometry of glucocorticoid-induced osteoporotic male Sprague-Dawley rats. Singap Med J 52:786-793
43. Al-Wahaibi A, Nazaimoon WWM, Farihah HS, Azian AL (2007) Effects of water extract of Labisia pumila var alata on 11beta-hydroxysteroid dehydrogenase activity induced fat deposition in the Sprague Dawley rats. Trop Med Plants 8:21-26
44. Cooper MS, Rabbit EH, Goddard PE, Bartiett WA, Hewison M, Stewart PM (2002) Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 17:979-986
45. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE (2008) Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 58:1674-1686
46. Delany AM, Gabbitas BY, Canalis E (1995) Cortisol downregulates osteoblast alpha 1 (I) procollagen mRNA by transcriptional and posttranscriptional mechanisms. J Cell Biochem 57:488-494
47. Strömstedt PE, Poellinger L, Gustafsson JA, Carlstedt-Duke J (1991) The glucocorticoid receptor binds to a sequence overlapping the TATA box of the human osteocalcin promoter: a potential mechanism for negative regulation. Mol Cell Biol 11:3379-3383
48. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
49. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
50. Cohen S (2006) Role of RANK ligand in normal and pathologic bone remodeling and the therapeutic potential of novel inhibitory molecules in musculoskeletal diseases. Arthritis Rheum 55:15-18
51. Sivagurunathan S, Muir MM, Brennan TC, Seale JP, Mason RS (2005) Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res 20:390-398